The Rebound Effect on Repeated Low-Level Red Light Therapy for Myopia
Starting soon · Not applicable
Conditions studied: Myopia, Randomized Controlled Trial (RCT)
In brief
Myopia is a global public health issue, projected to affect 49.8% of the world population by 2050, increasing risks of cataracts, glaucoma, macular degeneration, and retinal detachment. Repeated low-level red light (RLRL) therapy has shown promising myopia control in 12-month trials, reducing axial elongation by 69.4% and refractive progression by 76.6% versus spectacles, outperforming 0.01% atropine and benefiting orthokeratology poor responders. However, two-year data indicate declining efficacy in the second year and a rebound effect upon discontinuation, with progression rates matching untreated controls. This study enrolls participants who completed one year of continuous RLRL therapy to evaluate rebound effects on axial length and spherical equivalent refractive power among those who discontinue, gradually reduce, or continue treatment. Findings will inform strategies to optimize long-term RLRL protocols and mitigate post-treatment rebound.
Key facts
- Study ID
- NCT07748546
- Run by
- The First Affiliated Hospital of Anhui Medical University
- People needed
- 159
- Starts
- 2026-08-15
- Expected to finish
- 2028-07-15
- Last updated by the study team
- 2026-08-05
Who can join
Age: 8 and older, up to 16. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- 8 to 16 years old
- Rceived continuous RLRL treatment for 1 year (±1 month) without interruption.
- Diagnosed with myopia (ciliary muscle paralysis SER ≥ -0.50 D), astigmatism ≤ 2.50 D, anisometropia ≤ 1.50 D, and bilateral best corrected visual acuity (BCVA) ≥ Snellen 20/20 before receiving RLRL treatment.
- The consent of the guardian and the consent of the participant.
You may not qualify if…
- History of any ophthalmic surgery or ocular diseases (e.g., glaucoma, retinal disorders).
- Systemic diseases that affect vision or eye health (e.g., diabetes). After discontinuing RLRL treatment, other myopia control interventions other than monocular glasses should be employed (including atropine, orthokeratology lenses, defocused/DOT lenses, etc.).
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.